Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

989 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Searching for prostate cancer stem cells: markers and methods.
Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. Sharpe B, et al. Among authors: bowen r. Stem Cell Rev Rep. 2013 Oct;9(5):721-30. doi: 10.1007/s12015-013-9453-4. Stem Cell Rev Rep. 2013. PMID: 23775699 Review.
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom.
Leung EY, Nicum S, Morrison J, Brenton JD, Funingana IG, Morgan RD, Ghaem-Maghami S, Miles T, Manchanda R, Bowen R, Andreou A, Loughborough W, Freeman S, Gajjar K, Coleridge S, Jimenez-Linan M, Balega J, Frost J, Keightley A, Wallis Y, Sundar S, Ganesan R. Leung EY, et al. Among authors: bowen r. Int J Gynecol Cancer. 2024 Sep 2;34(9):1334-1343. doi: 10.1136/ijgc-2024-005756. Int J Gynecol Cancer. 2024. PMID: 39222974
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer.
Sundar S, Nordin A, Morrison J, Wood N, Ghaem-Maghami S, Nieto J, Phillips A, Butler J, Burton K, Gornall R, Dobbs S, Glasspool R, Peevor R, Ledermann J, McNeish I, Ratnavelu N, Duncan T, Frost J, Lim K, Michael A, Brockbank E, Gajjar K, Taylor A, Bowen R, Andreou A, Ganesan R, Nicum S, Edmondson R, Clayton R, Balega J, Rolland P, Maxwell H, Fotopoulou C. Sundar S, et al. Among authors: bowen r. Cancers (Basel). 2023 Jan 4;15(2):337. doi: 10.3390/cancers15020337. Cancers (Basel). 2023. PMID: 36672287 Free PMC article.
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA. George A, et al. Among authors: bowen r. Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6. Eur J Cancer. 2017. PMID: 28273485 Free article.
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Hall MR, Dehbi HM, Banerjee S, Lord R, Clamp A, Ledermann JA, Nicum S, Lilleywhite R, Bowen R, Michael A, Feeney A, Glasspool R, Hackshaw A, Rustin G. Hall MR, et al. Among authors: bowen r. Gynecol Oncol. 2020 Dec;159(3):692-698. doi: 10.1016/j.ygyno.2020.09.048. Epub 2020 Oct 16. Gynecol Oncol. 2020. PMID: 33077258 Clinical Trial.
Predictive markers in breast cancer--the present.
Payne SJ, Bowen RL, Jones JL, Wells CA. Payne SJ, et al. Among authors: bowen rl. Histopathology. 2008 Jan;52(1):82-90. doi: 10.1111/j.1365-2559.2007.02897.x. Histopathology. 2008. PMID: 18171419 Review.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. Earl HM, et al. Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178152 Free PMC article. Clinical Trial.
989 results